Compass Therapeutics (CMPX) News Today $0.76 +0.01 (+1.73%) Closing price 10/28/2026 04:00 PM EasternExtended Trading$0.76 +0.00 (+0.22%) As of 05:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Compass Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Compass Therapeutics, Inc. (CMPX) - What Are Researchers Thinking About This Stock?3 hours ago | americanbankingnews.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Stock Rated "Moderate Buy" by Sell-Side Brokerages3 hours ago | marketbeat.comCompass Therapeutics (CMPX) Set to Post Quarterly Earnings on WednesdayOctober 28 at 8:55 AM | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Stock Price Down 1.8% - Here's What HappenedOctober 27 at 2:01 AM | americanbankingnews.comCompass Therapeutics (NASDAQ:CMPX) Stock Price Down 1.8% - Should You Sell?October 27 at 1:59 AM | marketbeat.comCompass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026October 24, 2026 | globenewswire.comCompass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 14, 2026 | globenewswire.comCompass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory ConcernsOctober 13, 2026 | finance.yahoo.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Stock Has Average Target Price of $10.21October 4, 2026 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Stock: Insider Neil Lerner Purchases 20,000 SharesOctober 3, 2026 | insidertrades.comCompass Therapeutics (NASDAQ:CMPX) CAO Buys 20,000 Shares of StockOctober 2, 2026 | marketbeat.comCompass Therapeutics consensus price target decreased by 33.73% to $6.03October 2, 2026 | msn.comCompass Therapeutics’ FDA setback raises concerns on Wall Street — HC Wainwright calls Tovecimig filing strategy ‘risky’September 24, 2026 | msn.comWedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5September 23, 2026 | marketscreener.comMCompass Therapeutics: A Promising, But Shrinking, Window Of OpportunitySeptember 23, 2026 | seekingalpha.comCompass Therapeutics Shares Drop After Downgrade From WedbushSeptember 23, 2026 | finance.yahoo.comCompass Therapeutics (CMPX) was downgraded to a Hold Rating at LifeSci CapitalSeptember 23, 2026 | theglobeandmail.comCompass Therapeutics downgraded at Wedbush as FDA seeks additional trial for lead assetSeptember 23, 2026 | msn.comCompass Therapeutics Says FDA Recommends New Tovecimig Trial in Biliary Tract Cancer; Shares FallSeptember 22, 2026 | finance.yahoo.comCMPX plunge wipes out $104M after FDA demands fresh trial for cancer drug — Wedbush sees another 19% downsideSeptember 22, 2026 | msn.comCompass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer DrugSeptember 22, 2026 | benzinga.comCMPX stock crashes to over 2-year lows — why FDA wants another cancer therapy trial before key marketing filingSeptember 22, 2026 | msn.comCompass Therapeutics drops as FDA seeks additional trial for lead assetSeptember 22, 2026 | seekingalpha.comCompass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA FeedbackSeptember 22, 2026 | globenewswire.comCompass Therapeutics Reports Q2 2026 Results, Advances Tovecimig FDA Plans and Broadens Oncology PipelineAugust 6, 2026 | quiverquant.comQCompass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate UpdateAugust 6, 2026 | globenewswire.comCompass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026July 17, 2026 | markets.businessinsider.comCompass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026July 17, 2026 | globenewswire.comCMPX Share News TodayJuly 3, 2026 | uk.investing.comCompass Therapeutics Inc.June 28, 2026 | marketwatch.comCompass Therapeutics Adopts Second Amended and Restated BylawsJune 23, 2026 | tipranks.comHow Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer FilingJune 17, 2026 | insidermonkey.comCompass Therapeutics Shareholders Back Directors, Pay, Auditor OversightJune 11, 2026 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX)June 5, 2026 | theglobeandmail.comCompass Therapeutics Inc Ordinary Shares CMPXJune 2, 2026 | morningstar.comMStifel Nicolaus Sticks to Their Buy Rating for Compass Therapeutics (CMPX)June 2, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX)June 2, 2026 | theglobeandmail.comCompass Therapeutics to Participate in Upcoming June Investor EventsMay 28, 2026 | globenewswire.comCompass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ...May 23, 2026 | markets.businessinsider.comCompass Therapeutics Announces Promising Phase 1 Results for CTX-8371, Innovative Dual Checkpoint Blocker in Advanced MalignanciesMay 21, 2026 | quiverquant.comQCompass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual MeetingMay 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPXMay 21, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPXMay 19, 2026 | globenewswire.comCompass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3MMay 18, 2026 | finance.yahoo.comCompass Therapeutics (CMPX) price target decreased by 26.39% to 10.11May 16, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPXMay 14, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPXMay 12, 2026 | globenewswire.comCompass Therapeutics to Participate in Upcoming May Investor EventsMay 12, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Compass Therapeutics (CMPX) and Addus Homecare (ADUS)May 8, 2026 | theglobeandmail.comGuggenheim Remains a Buy on Compass Therapeutics (CMPX)May 7, 2026 | theglobeandmail.com Compass Therapeutics Media Mentions By Week Compass Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMPX News Sentiment▼0.510.68▲Average Healthcare News Sentiment Compass Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMPX Articles This Week▼54▲CMPX Articles Average Week Compass Therapeutics Trends on MarketBeatThis week vs. last weekSearches1-50%Page Views2,106-22% Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies WVE News NVCT News AVTX News SLDB News IRWD News OLMA News IMMX News DBVT News CLYM News STTK News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Compass Therapeutics dated 10/29/2026. From Our PartnersThe cash in your checking account has a problemThere's a pile of cash sitting in your checking account, earning next to nothing while you weigh your options....Counterflow | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
